October 26-27 2020 Boston, MA
Dr. Mousses is the cofounder and CEO of Systems Oncology LLC. He is widely recognized as a leading scientist in the application of genomics, systems biology, and machine learning to improve and accelerate cancer drug discovery and development. Previously he served as Vice President and Director of the Pharmaceutical Genomics Division at the Translational Genomics Research Institute (TGen), where he led 8 laboratories to develop more than 30 programs and collaborated with dozens of pharmaceutical partners to accelerate cancer drug development. Prior to that, he served as Staff Scientist at the National Human Genome Research Institute (NHGRI), NIH, leading a program in cancer genome scanning and high throughput technology. As a successful entrepreneur, Dr. Mousses has previously founded several biotech and IT companies, including Systems Medicine (acquired by Cell Therapeutics), MedTrust Online (acquired by Annai Systems), and Systems Imagination (acquired by Systems Oncology). Currently, Systems Oncology is applying advanced cognitive computing technology to translate big data into biomedical insights, which in turn have enabled the creation of a rapidly growing pipeline of innovative cancer therapeutics. Dr. Mousses received his PhD in Molecular Pathogenesis and Genetics of Cancer from the University of Toronto.
DAY 1 / Tuesday October 27th
Use Case: Application of AI to Predict a New Class of Novel Synthetic Lethal Targets Leading to More Effective and Safer Oncology Therapeutic Programs
- AI research and insights using the ExpansiveAI platform
- Scalable mining of data connections, testing masses of hypotheses, cognitive computing and ML to discover novel targets
- Bioinformatic filtering, in-silico validation, prioritizing targets aimed at vulnerable cancer cells harboring a specific gene change
- Launching new effective and safer therapeutic programs